P. Terheyden

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

J. Utikal, C. Berking, S. Löck, 2019, European journal of cancer.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

J. Utikal, C. Berking, J. Klode, 2019, European journal of cancer.

Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

S. Haferkamp, M. Gaiser, R. Gutzmer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.

J. Utikal, D. Schadendorf, A. Gesierich, 2023, European journal of cancer.

Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

S. Haferkamp, K. Kähler, W. Peitsch, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.